Clarithromycin versus metronidazole as first-line helicobacter pylori eradication

Toshihiro Nishizawa, Takama Maekawa, Noriko Watanabe, Naohiko Harada, Yasuo Hosoda, Masahiro Yoshinaga, Toshiyuki Yoshio, Hajime Ohta, Syuuji Inoue, Tatsuya Toyokawa, Haruhiro Yamashita, Hiroki Saito, Toshio Kuwai, Shunsuke Katayama, Eiji Masuda, Hideharu Miyabayashi, Toshio Kimura, Yuko Nishizawa, Masahiko Takahashi, Hidekazu Suzuki

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background: Helicobacter pylori eradication rates achieved with a first-line regimen of clarithromycin (CLR) combined with amoxicillin (AMX) and a proton pump inhibitor have recently fallen to ≤80% because of the increasing incidence of CLR resistance in Japan. This randomized multicenter trial aimed to compare the eradication success of 2 first-line triple therapy regimens: rabeprazole, amoxicillin, and clarithromycin (RAC) versus rabeprazole, amoxicillin, and metronidazole (RAM). Methods: A total of 124 consecutive patients infected with H. pylori were randomized into one of two 7-day therapeutic regimens: RAC (n=60) or RAM (n=64). Eradication was confirmed by the 13 C-urea breath test. Adverse effects were also assessed. Results: Intention-to-treat and per protocol H. pylori eradication rates were 73.3%/77.2% in the RAC group and 90.6%/93.5% in the RAM group. The eradication rate of RAM therapy was significantly higher than that of RAC therapy. CLR, metronidazole, and AMX resistance was found in 36.2%, 2.1%, and 0% of patients, respectively. In addition, no relevant differences in adverse effects were observed. Conclusions: Metronidazole-based therapy (RAM) was superior to standard CLR-based therapy (RAC) for first-line H. pylori eradication. This reflects the progressive increase in CLR resistance observed in Japan.

Original languageEnglish
Pages (from-to)468-471
Number of pages4
JournalJournal of Clinical Gastroenterology
Volume49
Issue number6
DOIs
Publication statusPublished - 2015 Jun 24

Fingerprint

Rabeprazole
Clarithromycin
Amoxicillin
Metronidazole
Helicobacter pylori
Japan
Therapeutics
Breath Tests
Proton Pump Inhibitors
Multicenter Studies
Urea

Keywords

  • clarithromycin
  • eradication
  • Helicobacter pylori
  • metronidazole

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Nishizawa, T., Maekawa, T., Watanabe, N., Harada, N., Hosoda, Y., Yoshinaga, M., ... Suzuki, H. (2015). Clarithromycin versus metronidazole as first-line helicobacter pylori eradication. Journal of Clinical Gastroenterology, 49(6), 468-471. https://doi.org/10.1097/MCG.0000000000000165

Clarithromycin versus metronidazole as first-line helicobacter pylori eradication. / Nishizawa, Toshihiro; Maekawa, Takama; Watanabe, Noriko; Harada, Naohiko; Hosoda, Yasuo; Yoshinaga, Masahiro; Yoshio, Toshiyuki; Ohta, Hajime; Inoue, Syuuji; Toyokawa, Tatsuya; Yamashita, Haruhiro; Saito, Hiroki; Kuwai, Toshio; Katayama, Shunsuke; Masuda, Eiji; Miyabayashi, Hideharu; Kimura, Toshio; Nishizawa, Yuko; Takahashi, Masahiko; Suzuki, Hidekazu.

In: Journal of Clinical Gastroenterology, Vol. 49, No. 6, 24.06.2015, p. 468-471.

Research output: Contribution to journalArticle

Nishizawa, T, Maekawa, T, Watanabe, N, Harada, N, Hosoda, Y, Yoshinaga, M, Yoshio, T, Ohta, H, Inoue, S, Toyokawa, T, Yamashita, H, Saito, H, Kuwai, T, Katayama, S, Masuda, E, Miyabayashi, H, Kimura, T, Nishizawa, Y, Takahashi, M & Suzuki, H 2015, 'Clarithromycin versus metronidazole as first-line helicobacter pylori eradication', Journal of Clinical Gastroenterology, vol. 49, no. 6, pp. 468-471. https://doi.org/10.1097/MCG.0000000000000165
Nishizawa, Toshihiro ; Maekawa, Takama ; Watanabe, Noriko ; Harada, Naohiko ; Hosoda, Yasuo ; Yoshinaga, Masahiro ; Yoshio, Toshiyuki ; Ohta, Hajime ; Inoue, Syuuji ; Toyokawa, Tatsuya ; Yamashita, Haruhiro ; Saito, Hiroki ; Kuwai, Toshio ; Katayama, Shunsuke ; Masuda, Eiji ; Miyabayashi, Hideharu ; Kimura, Toshio ; Nishizawa, Yuko ; Takahashi, Masahiko ; Suzuki, Hidekazu. / Clarithromycin versus metronidazole as first-line helicobacter pylori eradication. In: Journal of Clinical Gastroenterology. 2015 ; Vol. 49, No. 6. pp. 468-471.
@article{cf88113916a34bf68129e32e7f519448,
title = "Clarithromycin versus metronidazole as first-line helicobacter pylori eradication",
abstract = "Background: Helicobacter pylori eradication rates achieved with a first-line regimen of clarithromycin (CLR) combined with amoxicillin (AMX) and a proton pump inhibitor have recently fallen to ≤80{\%} because of the increasing incidence of CLR resistance in Japan. This randomized multicenter trial aimed to compare the eradication success of 2 first-line triple therapy regimens: rabeprazole, amoxicillin, and clarithromycin (RAC) versus rabeprazole, amoxicillin, and metronidazole (RAM). Methods: A total of 124 consecutive patients infected with H. pylori were randomized into one of two 7-day therapeutic regimens: RAC (n=60) or RAM (n=64). Eradication was confirmed by the 13 C-urea breath test. Adverse effects were also assessed. Results: Intention-to-treat and per protocol H. pylori eradication rates were 73.3{\%}/77.2{\%} in the RAC group and 90.6{\%}/93.5{\%} in the RAM group. The eradication rate of RAM therapy was significantly higher than that of RAC therapy. CLR, metronidazole, and AMX resistance was found in 36.2{\%}, 2.1{\%}, and 0{\%} of patients, respectively. In addition, no relevant differences in adverse effects were observed. Conclusions: Metronidazole-based therapy (RAM) was superior to standard CLR-based therapy (RAC) for first-line H. pylori eradication. This reflects the progressive increase in CLR resistance observed in Japan.",
keywords = "clarithromycin, eradication, Helicobacter pylori, metronidazole",
author = "Toshihiro Nishizawa and Takama Maekawa and Noriko Watanabe and Naohiko Harada and Yasuo Hosoda and Masahiro Yoshinaga and Toshiyuki Yoshio and Hajime Ohta and Syuuji Inoue and Tatsuya Toyokawa and Haruhiro Yamashita and Hiroki Saito and Toshio Kuwai and Shunsuke Katayama and Eiji Masuda and Hideharu Miyabayashi and Toshio Kimura and Yuko Nishizawa and Masahiko Takahashi and Hidekazu Suzuki",
year = "2015",
month = "6",
day = "24",
doi = "10.1097/MCG.0000000000000165",
language = "English",
volume = "49",
pages = "468--471",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Clarithromycin versus metronidazole as first-line helicobacter pylori eradication

AU - Nishizawa, Toshihiro

AU - Maekawa, Takama

AU - Watanabe, Noriko

AU - Harada, Naohiko

AU - Hosoda, Yasuo

AU - Yoshinaga, Masahiro

AU - Yoshio, Toshiyuki

AU - Ohta, Hajime

AU - Inoue, Syuuji

AU - Toyokawa, Tatsuya

AU - Yamashita, Haruhiro

AU - Saito, Hiroki

AU - Kuwai, Toshio

AU - Katayama, Shunsuke

AU - Masuda, Eiji

AU - Miyabayashi, Hideharu

AU - Kimura, Toshio

AU - Nishizawa, Yuko

AU - Takahashi, Masahiko

AU - Suzuki, Hidekazu

PY - 2015/6/24

Y1 - 2015/6/24

N2 - Background: Helicobacter pylori eradication rates achieved with a first-line regimen of clarithromycin (CLR) combined with amoxicillin (AMX) and a proton pump inhibitor have recently fallen to ≤80% because of the increasing incidence of CLR resistance in Japan. This randomized multicenter trial aimed to compare the eradication success of 2 first-line triple therapy regimens: rabeprazole, amoxicillin, and clarithromycin (RAC) versus rabeprazole, amoxicillin, and metronidazole (RAM). Methods: A total of 124 consecutive patients infected with H. pylori were randomized into one of two 7-day therapeutic regimens: RAC (n=60) or RAM (n=64). Eradication was confirmed by the 13 C-urea breath test. Adverse effects were also assessed. Results: Intention-to-treat and per protocol H. pylori eradication rates were 73.3%/77.2% in the RAC group and 90.6%/93.5% in the RAM group. The eradication rate of RAM therapy was significantly higher than that of RAC therapy. CLR, metronidazole, and AMX resistance was found in 36.2%, 2.1%, and 0% of patients, respectively. In addition, no relevant differences in adverse effects were observed. Conclusions: Metronidazole-based therapy (RAM) was superior to standard CLR-based therapy (RAC) for first-line H. pylori eradication. This reflects the progressive increase in CLR resistance observed in Japan.

AB - Background: Helicobacter pylori eradication rates achieved with a first-line regimen of clarithromycin (CLR) combined with amoxicillin (AMX) and a proton pump inhibitor have recently fallen to ≤80% because of the increasing incidence of CLR resistance in Japan. This randomized multicenter trial aimed to compare the eradication success of 2 first-line triple therapy regimens: rabeprazole, amoxicillin, and clarithromycin (RAC) versus rabeprazole, amoxicillin, and metronidazole (RAM). Methods: A total of 124 consecutive patients infected with H. pylori were randomized into one of two 7-day therapeutic regimens: RAC (n=60) or RAM (n=64). Eradication was confirmed by the 13 C-urea breath test. Adverse effects were also assessed. Results: Intention-to-treat and per protocol H. pylori eradication rates were 73.3%/77.2% in the RAC group and 90.6%/93.5% in the RAM group. The eradication rate of RAM therapy was significantly higher than that of RAC therapy. CLR, metronidazole, and AMX resistance was found in 36.2%, 2.1%, and 0% of patients, respectively. In addition, no relevant differences in adverse effects were observed. Conclusions: Metronidazole-based therapy (RAM) was superior to standard CLR-based therapy (RAC) for first-line H. pylori eradication. This reflects the progressive increase in CLR resistance observed in Japan.

KW - clarithromycin

KW - eradication

KW - Helicobacter pylori

KW - metronidazole

UR - http://www.scopus.com/inward/record.url?scp=84932193569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932193569&partnerID=8YFLogxK

U2 - 10.1097/MCG.0000000000000165

DO - 10.1097/MCG.0000000000000165

M3 - Article

C2 - 24921211

AN - SCOPUS:84932193569

VL - 49

SP - 468

EP - 471

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 6

ER -